Carcinoid Tumor
Information
- Disease name
- Carcinoid Tumor
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03375320 | Active, not recruiting | Phase 3 | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | October 26, 2018 | May 3, 2025 |
| NCT05477576 | Active, not recruiting | Phase 3 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | March 24, 2022 | July 2028 |
| NCT05361668 | Active, not recruiting | Phase 2 | Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome | June 17, 2022 | February 2026 |
| NCT02399215 | Completed | Phase 2 | Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | May 15, 2015 | August 31, 2022 |
| NCT00780663 | Completed | Phase 2 | Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | October 2008 | March 2010 |
| NCT00804336 | Completed | Phase 1 | Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | October 2008 | April 2015 |
| NCT00942682 | Completed | Phase 1 | Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | July 2009 | March 2013 |
| NCT01024387 | Completed | Phase 2 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | March 2010 | January 2017 |
| NCT00328497 | Completed | Phase 2 | A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors | May 2006 | December 2009 |
| NCT04197310 | Completed | Phase 2 | Cabozantinib and Nivolumab for Carcinoid Tumors | December 26, 2019 | January 31, 2024 |
| NCT01398306 | Completed | Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | July 2011 | April 2012 | |
| NCT01435122 | Completed | Phase 2 | A Study of Axitinib in Advanced Carcinoid Tumors | October 25, 2011 | February 13, 2018 |
| NCT01466036 | Completed | Phase 2 | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | July 2012 | December 2023 |
| NCT01782443 | Completed | Phase 2 | Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors | February 13, 2013 | December 26, 2021 |
| NCT03723499 | Completed | Endoscopic Treatment of Bronchial Carcinoid Tumors | November 1995 | December 2017 | |
| NCT00412061 | Completed | Phase 3 | Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor | December 2006 | June 2013 |
| NCT00446082 | Completed | Phase 1 | Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease | June 2006 | November 2013 |
| NCT02431715 | No longer available | 18F-FDOPA PET in Neuroendocrine Tumours | |||
| NCT04039516 | Not yet recruiting | Phase 2 | Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy | October 2020 | December 2024 |
| NCT02628067 | Recruiting | Phase 2 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | December 18, 2015 | May 4, 2027 |
| NCT02754297 | Recruiting | Phase 2 | Personalized PRRT of Neuroendocrine Tumors | April 12, 2016 | April 12, 2029 |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04907643 | Recruiting | N/A | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | October 5, 2021 | March 2026 |
| NCT04993261 | Recruiting | Early Phase 1 | An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors | September 23, 2015 | December 31, 2026 |
| NCT01039922 | Recruiting | SwissNET - a Registry for Neuroendocrine Tumours in Switzerland | January 2008 | January 2028 | |
| NCT05636618 | Recruiting | Phase 1/Phase 2 | Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors | September 27, 2023 | January 31, 2028 |
| NCT04017104 | Recruiting | Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging | November 1, 2019 | August 1, 2024 | |
| NCT03420521 | Terminated | Phase 2 | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | March 9, 2018 | November 24, 2021 |
| NCT02038738 | Unknown status | Phase 1/Phase 2 | 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | March 2014 | |
| NCT01175096 | Unknown status | Phase 1/Phase 2 | Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor | July 2010 | January 2012 |
| NCT00657332 | Withdrawn | Clinical and Pathologic Studies in Neuroendocrine Tumors | July 2007 | June 17, 2008 | |
| NCT04915144 | Withdrawn | Phase 2 | 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | January 15, 2023 | December 31, 2031 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0100570
- MeSH unique ID (MeSH (Medical Subject Headings))
- D002276